💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Finasteride

CHEMBL710 Phase 4 Onaylandı Small molecule
Half-Life
5-6 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
372.5 g/mol
LogP
3.0
Phase
4

This medication works by blocking an enzyme that converts testosterone into a more potent hormone called dihydrotestosterone, which drives prostate growth and male-pattern hair loss. It is used to shrink an enlarged prostate and relieve urinary symptoms, as well as to treat male hair loss.

Moleküler Ağırlık

372,5490 g/mol

LogP

3,00

TPSA

58,20 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Benign Prostatic Hyperplasia Non-Small Cell Lung Cancer Breast Cancer HIV/AIDS Prostate Cancer

İlaç Sınıfları

G — G - Genito-Urinary System and Sex Hormones

Etki Mekanizması

Competitive inhibitor of 5-alpha-reductase type II.

Pharmacokinetics (PK)

Half-Life 5-6 hours

Pharmacodynamics (PD)

Mekanizma

Competitive inhibitor of 5-alpha-reductase type II.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C

                

                

                
                

                    
InChI

                    
InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H36N2O2

                    

                    
                    

                        
HBD / HBA

                        
2 / 2

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
2

                    

                    
                    
                    

                        
Ağır Atomlar

                        
27

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            PPARG (Peroxisome Proliferator-Activated Receptor Gamma)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Finasteride + Tamsulosin
                            
                        

                        
                        
Finasteride and tamsulosin are deliberately combined (as Duodart/Jalyn) for BPH treatment; the combination provides additive symptom relief with no significant adverse pharmacokinetic interaction.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Finasteride + Fluconazole
                            
                        

                        
                        
Fluconazole inhibits CYP3A4, which contributes to finasteride metabolism; co-administration may modestly increase finasteride plasma concentrations, though the clinical significance is generally low.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Finasteride + Doxycycline
                            
                        

                        
                        
No clinically significant pharmacokinetic or pharmacodynamic interaction is established between doxycycline and finasteride; they are occasionally co-prescribed in patients with androgenetic alopecia and concomitant infections.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
This medication works by blocking an enzyme that converts testosterone into a more potent hormone called dihydrotestosterone, which drives prostate growth and male-pattern hair loss. It is used to shrink an enlarged prostate and relieve urinary symptoms, as well as to treat male hair loss.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitive inhibitor of 5-alpha-reductase type II.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Finasteride: Half-life: 5-6 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Finasteride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Sildenafil
                            Small molecule
                        
                        
                        
                            Tamsulosin
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL710.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 57363.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.